Abstract
Acute myocardial infarction is related to plaque rupture and thrombosis formation in the infarct-related coronary artery. Salvage of ischemic area with thrombolysis in the early stage of infarction has proved to be the best way to limit infarct size, preserve left ventricular function and reduce mortality in the majority of victims. Tissue plasminogen activator (tPA) is the most promising thrombolytic agent used to salvage ischemic myocardium; the efficacy has been systematically demonstrated in previous studies (1–4).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. R. Bergmann, K. A. A. Fox, M. M. Ter-Pogossian, and D. Sobel. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 220:1181–3 (1983).
B. Sobel, Early intervention in acute myocardial infarction: One center’s perspective, Am. J. Cardiol., 69:983–990 (1984).
B. E. Sobel, R. W. Gross, and A. K. Robinson, Thrombolysis, clot selectivity and kinetics, Circulation, 70:160–164 (1984).
A. J. Tiefenbrunn, A. K. Robinson, P. B. Kurnik, P. A. Ludbrook and B. E. Sobel, Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology, Circulation, 71:110–116 (1985).
L Campeau, Grading of angina pectoris, Circulation, 54:522 (1976).
M. A. DeWood, J. Spores, R. Notske, L. T. Mouser, R. Burroughs, M. S. Golden, and H. T. Lang, Prevalence of total coronary occlusion during the early hours of transluminal myocardial infarction, N. Engl. J. Med.,303:897 (1980).
The TIMI study group, The thrombolysis in myocardial infarction (TIMI) trial, N. Engl. J. Med., 312:923–6 (1985).
M. Verstraete, M. Bory, and D. Collen, et al., Randomized trial of intravenous recombinant tissue-typed plasminogen activator versus intravenous streptokinase in acute myocardial infarction, Lancet, 2:965–969 (1985).
J. H. Chesebro, G. Knatterud, and R. Roberts, et al., Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase, clinical findings through hospital discharge, Circulation, 76:142–154 (1987).
A. K. Rao, C. Pratt, and A. Berke, et al., Thrombolysis in myocardial infarction (TIMI) trial- Phase I: Hemorrhagic manifestation and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase, J. Am. Coll. Cardiol., 11:1–11 (1988).
D. O. Williams, J. Borer, E. Braunwald, et al. Intravenous recombinant tissue-typed plasminogen activator in patients with acute myocardial infarction: A report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 73:338–346 (1986).
F. H. Sheehan, D. F. Mathey, J. Schofer, et al., Limitations in the interpretation of rest-exercise ejection fraction changes after early thrombolytic therapy during acute myocardial infarction. Am. J. Cardiol., 61:743–748 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wang, SP., Chang, MS., Chiang, B.N. (1990). Clinical Application of Tissue Plasminogen Activator Therapy in Acute Myocardial Infarction. In: Liu, C.Y., Chien, S. (eds) Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis. Advances in Experimental Medicine and Biology, vol 281. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3806-6_42
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3806-6_42
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6697-3
Online ISBN: 978-1-4615-3806-6
eBook Packages: Springer Book Archive